Latest news
Lung Cancer May Be Entering the Chemo-Replacement Fight
Phase III data reported in The Lancet and highlighted this week show sacituzumab tirumotecan plus pembrolizumab improved progression-free survival versus pembrolizumab alone in PD-L1-positive advanced NSCLC. The ADC era is moving into first-line lung cancer, but toxicity and sequencing will decide how far it goes.
ADA 2026 findings show diabetes drugs are no longer just chasing glucose
Oral SERDs Face the Hard Test: Where Do They Actually Fit?
Prostate Cancer Value Starts Counting Cognition
China’s PD-1/VEGF Bet Challenges the Lung Cancer Backbone
The ASCO Drug Race Still Runs Through Genomic Testing
High-Risk Prostate Cancer Moves Before the Metastatic Clock Starts
Servier’s $2.65B Muscular Dystrophy Deal Turns Rare Neurology Into a Commercial Priority
Alzheimer’s Blood Testing Moves the Disease Clock Earlier
Lenacapavir Turns HIV Prevention Into an Access Stress Test
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.